Prognostic differences in 8th edition TNM staging of esophagogastric adenocarcinoma after neoadjuvant treatment-Reference-Cited by-同舟云学术

Prognostic differences in 8th edition TNM staging of esophagogastric adenocarcinoma after neoadjuvant treatment

Published:2018-10 Issue:10 Volume:44 Page:1646-1656
ISSN:0748-7983
Container-title:European Journal of Surgical Oncology
language:en
Short-container-title:European Journal of Surgical Oncology

Author:

Sisic Leila,Blank Susanne,Nienhüser Henrik,Dorr Sara,Haag Georg Martin,Jäger Dirk,Bruckner Thomas,Müller-Stich Beat P.,Ott Katja,Büchler Markus W.,Ulrich Alexis,Schmidt Thomas^ORCID

Funder

University of Heidelberg medical faculty

Publisher

Elsevier BV

Subject

Oncology,General Medicine,Surgery

Reference42 articles.

1. 7th edition of the AJCC cancer staging manual: stomach;Washington;Ann Surg Oncol,2010

2. Evaluation of the seventh American joint committee on cancer/international union against cancer classification of gastric adenocarcinoma in comparison with the sixth classification;Ahn;Cancer,2010

3. Worldwide esophageal cancer collaboration;Rice;Dis Esophagus,2009

4. (Neo)-adjuvant chemo(-radio) therapy for adenocarcinomas of the gastroesophageal junction and the stomach in the West;Wilke;Dig Surg,2013

5. Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy;Nomura;Int J Radiat Oncol Biol Phys,2012

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a novel staging classification for Siewert II adenocarcinoma of the esophagogastric junction after neoadjuvant chemotherapy;World Journal of Gastrointestinal Oncology;2024-06-15

2. Prognostic factors in clinicopathology of oesophagogastric adenocarcinoma: a single-centre longitudinal study of 347 cases over a 20-year period;Pathology;2024-06

3. Esophageal adenocarcinoma heterogeneity in clinicopathology and prognosis: A single center longitudinal study of 146 cases over a 20-year period;Annals of Diagnostic Pathology;2024-06

4. Short-term Outcomes of Adjuvant Nivolumab After Neoadjuvant Chemotherapy in Patients With Resected Esophageal Squamous Cell Carcinoma;Anticancer Research;2023-12-30

5. Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial;Frontiers in Immunology;2023-10-04